Select your language

Other official information and services: www.belgium.be  belgium

  • Key figures
  •  Data
  • Graphics
  • Comments
PRESCRIBERS
Main prescribers: General practitioners 78.04%
INSURED CONSUMERS
% of insured consumers 8.62%
Median age 72 years
Max/min ratio of the median age (by district) 1.06
Percentage of women 46.35%
Ratio Preferential scheme/General scheme 1.35
Coefficient of variation (2022) 11.21
Max/min ratio of % of insured consumers (by district) 1.56
CONSUMPTION
Annual consumption (DDD) 355,751,974
Consumption of DDD (per 100,000 insured persons) 3,091,103.18
% DDD issued outside the insurance (approximate) 3.68%
Average annual consumption per insured consumer (DDD) 358.46
% of insured consumers with > 3 times the average consumption 0,40%
Coefficient of variation 2013-2015 11.80
Coefficient of variation 2020-2022 12.88
Trend 2013-2022 -0.78%
Trend 2013-2019 0.37%
Trend 2019-2022 -3.04%
DIRECT EXPENDITURE (DDD)
Annual expenditure charged to the insurance 26,495,839
Average annual expenditure per insured person 2.30
Average patient share per insured consumer 14.47%
Max/min ratio of expenditure per insured person (by disctrict) 1.63
% “Low-cost” medication 10.99%
Trend 2013-2022 -3.45%
Trend 2019-2022 -4.25%


On this table, when a statistical test has been performed, the data showing a significant difference is displayed on an yellow background, otherwise on a grey background.

CODES (ATC-5) LABELS
B01AC PLATELET AGGREGATION INHIBITORS EXCL. HEPARIN

The codes mentioned above can be used in rates and expenses, or only in expenses. We invite you to consult the full report for more information.

Click below to see the graph illustrating the evolution of the breakdown by volume of ATC codes used for the rates.

Antiaggregants (2022)

No selection

2022

  • ATC codesATC codes
  • Age Sex CVAge, sex and CV
  • Rates by sexRates by sex
  • Reimbursement rateReimbursement rate
  • TrendsTrends by region
  • Trends breakTrends break
  • Dot PlotDot Plot
  • Funnel PlotFunnel plot
  • Provincial consumptionDDD per patient by province
  • DDD patientQuantity per patient
  • MapDistribution map
  • Low-costLow-cost DDD


WE ARE INTERESTED IN YOUR OPINION

Do you have any experience in this area ? We listen to you !

Send us an email

   Download the full report
 Download the methodology